Literature DB >> 7094977

Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

B Breithaupt, M Tittel.   

Abstract

An high-pressure liquid chromatographic method was used to measure allopurinol and oxipurinol in plasma and urine in 6 healthy volunteers after a single intravenous or oral dose of allopurinol. The influence of coadministered benzbromarone and hydrochlorothiazide on the pharmacokinetics of allopurinol and oxipurinol was also investigated. After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min. The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg. Oxipurinol disappeared monoexponentially from plasma with a mean half-life of 12.2 +/- 2.6 h. Its renal clearance was 0.42 +/- 0.091 ml/min/kg. After oral administration of allopurinol 300 mg the peak plasma concentration of 2.1 +/- 0.6 micrograms/ml (1.5 x 10(-5) M) was reached within 30 to 120 min. The peak level of oxipurinol of 5.8 +/- 1.5 micrograms/ml (3.8 x 10(-5) M) was found within 2 to 5 h after intravenous and oral allopurinol. The bioavailability of oral allopurinol computed from plasma data was 90.4 +/- 8.7%. The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration. It was concluded that about 10% of the oral dose was not absorbed and that 12% was eliminated by an unknown mechanism, presumably as riboside. The pharmacokinetics of allopurinol and oxipurinol were not significantly influenced by coadministration of benzbromarone or hydrochlorothiazide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094977     DOI: 10.1007/BF00606429

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Allopurinol sensitivity: report of two cases.

Authors:  D B Haughey; S Lanse; T Imhoff; M Tobin; J J Schentag
Journal:  Am J Hosp Pharm       Date:  1979-10

2.  [Action of benzbromarone on the renal excretion of allantoin in normouricemic and hyperuricemic humans (author's transl)].

Authors:  D Janzen; D P Mertz; E Scheiffele; O Kühnhold
Journal:  Klin Wochenschr       Date:  1977-11-01

3.  Allopurinol hypersensitivity.

Authors:  M W McKendrick; A M Geddes
Journal:  Br Med J       Date:  1979-04-14

4.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

5.  An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.

Authors:  W N Kelley; F M Rosenbloom; J Miller; J E Seegmiller
Journal:  N Engl J Med       Date:  1968-02-08       Impact factor: 91.245

6.  Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol.

Authors:  H A Simmonds
Journal:  Clin Chim Acta       Date:  1969-02       Impact factor: 3.786

7.  High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma.

Authors:  W G Kramer; S Feldman
Journal:  J Chromatogr       Date:  1979-01-01

8.  Determination of allopurinol and oxipurinol in biological fluids by high-performance liquid chromatography.

Authors:  H Breithaupt; G Goebel
Journal:  J Chromatogr       Date:  1981-11-13

9.  [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].

Authors:  I Walter-Sack; W Gröbner; N Zöllner
Journal:  Arzneimittelforschung       Date:  1979

10.  The allopurinol hypersensitivity syndrome.

Authors:  G P Lupton; R B Odom
Journal:  J Am Acad Dermatol       Date:  1979-10       Impact factor: 11.527

View more
  18 in total

1.  Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Authors:  Daniel Y Ng; Sophie L Stocker; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Eur J Clin Pharmacol       Date:  2010-12-23       Impact factor: 2.953

2.  Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Authors:  Solène M Laville; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

3.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

4.  Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption.

Authors:  K Balon; B U Riebesehl; B W Müller
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

5.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?

Authors:  I Walter-Sack; J X de Vries; C Kreiner; A Ittensohn; G Stenzhorn; A Voss; E Weber
Journal:  Clin Investig       Date:  1993-03

7.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

8.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

9.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.

Authors:  J X de Vries; A Voss; A Ittensohn; I Walter-Sack; W Löffler; R Landthaler; N Zöllner
Journal:  Clin Investig       Date:  1994-12

10.  The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.

Authors:  F O Müller; R Schall; G Groenewoud; H K Hundt; J C van der Merwe; M van Dyk
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.